.jpg)
Novo Nordisk follows Eli Lilly with its own ‘triple-G’ drug
Novo Nordisk said it's licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.
Good morning. Today, we discuss the implications of 23andMe’s bankruptcy and more news from the obesity space.
The need-to-know this morning
- Merck has acquired an experimental, oral drug that targets lipoprotein(a) for the treatment of cardiovascular disease from China’s Jiangsu Hengrui Pharmaceuticals. Merck paid $200 million in upfront cash for global rights to the drug, outside of China. Hengrui is eligible to receive another $1.8 billion in potential milestone payments.
- Scholar Rock said regulators in the U.S. and Europe accepted its marketing application for apitegromab as a treatment for spinal muscular atrophy. The FDA decision is expected on or before Sept. 22.
Novo licenses an obesity from China
Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.
